Market revenue in 2023 | USD 0.3 million |
Market revenue in 2030 | USD 0.7 million |
Growth rate | 10.9% (CAGR from 2023 to 2030) |
Largest segment | Neurology |
Fastest growing segment | Neurology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Dental, Orthopedic, Neurology |
Key market players worldwide | GlaxoSmithKline, Hewlett Packard Enterprise Co, Merck KGaA, AstraZeneca PLC, Aprecia Pharmaceuticals, Extend Biosciences, BioDuro, Affini-T Therapeutics, Osmotica Pharmaceutical, FabRx, Cycle Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to 3d printed drugs market will help companies and investors design strategic landscapes.
Neurology was the largest segment with a revenue share of 66.67% in 2023. Horizon Databook has segmented the Norway 3d printed drugs market based on dental, orthopedic, neurology covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical sector in Norway is expanding, particularly precision medicine. Norway is considered a lucrative country for pharmaceutical companies planning to establish an office or partner due to its strong history in the biomedical sciences. While Norway's healthcare system is known for its high quality, it does face challenges related to healthcare expenditure and the availability of healthcare professionals.
Moreover, Norway's proactive approach to embracing digitalization and technology in healthcare contributes to the growth of 3D printed drugs market. The government's support and initiatives to encourage the adoption of advanced manufacturing technologies, including 3D printing, highlight the nation's commitment to fostering innovation in healthcare.
By promoting research, development, collaborations, and investment in 3D printed drugs, Norway aims to enhance drug efficiency, dosage accuracy, and patient outcomes. This strategy positions the nation at the forefront of the evolving pharmaceutical manufacturing and healthcare innovation landscape, making Norway an emerging hub for 3D printed drugs.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway 3d printed drugs market , including forecasts for subscribers. This country databook contains high-level insights into Norway 3d printed drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account